The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer"

American Journal of Surgical Pathology

Volumn 35, Issue 4, 2011, Pages 608-614

  He, Huiying ^a   Magi Galluzzi, Cristina ^a   Li, Jianbo ^b   Carver, Paula ^a   Falzarano, Sara ^a   Smith, Karen ^a   Rubin, Mark A ^c   Zhou, Ming ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ATYP; atypical glands suspicious for cancer; ERG; immunohistochemistry; Prostate cancer; TMPRSS2 ERG gene fusion

Indexed keywords

ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ARTICLE; ATROPHY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METAPLASIA; NEEDLE BIOPSY; PATHOLOGY; PRECANCER; PROGNOSIS; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS;

ATROPHY; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953169828     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31820bcd2d     Document Type: Article

References (24)

1. Abouassaly R, Tan N, Moussa A, et al. Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol. 2008;180:911-914; discussion 914.
2. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826-832. (Pubitemid 44564838)
3. Chen ME, Troncoso P, Tang K, et al. Comparison of prostate biopsy schemes by computer simulation. Urology. 1999;53:951-960. (Pubitemid 29196311)
4. Cheville JC, Reznicek MJ, Bostwick DG. The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol. 1997; 108:633-640. (Pubitemid 27506229)
5. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;6:429-439.
6. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667-2673. (Pubitemid 46632014)
7. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985-1992.
8. De Marzo AM, Platz EA, Epstein JI, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006;30:1281-1291. (Pubitemid 44454708)
9. Delongchamps NB, Haas GP. Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol. 2009;6: 645-652.
10. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175:820-834. (Pubitemid 43199991)
11. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2008;21:67-75. (Pubitemid 351172158)
12. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-237.
13. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neo-plasia and potential clinical implications. Clin Cancer Res. 2008;14: 3380-3385.
14. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15: 4706-4711.
15. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590-598.
16. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888. (Pubitemid 47165141)
17. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent over-expression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24:3847-3852. (Pubitemid 40826884)
18. Rostad K, Mannelqvist M, Halvorsen OJ, et al. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol. 2007;30:19-32.
19. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061-1067.
20. Schoenfield L, Jones JS, Zippe CD, et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int. 2007;99:770-774. (Pubitemid 46439582)
21. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648. (Pubitemid 41528150)
22. Wolters T, van der Kwast TH, Vissers CJ, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010;34:35-43.
23. Zhou M, Magi-Galluzzi C Clinicopathological features of prostate cancers detected after an initial diagnosis of 'atypical glands suspicious for cancer'. Pathology. 2010;42:334-338.
24. Zhou M, Shah R, Shen R, et al. Basal cell cocktail (34beta E12+p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003;27:365-371. (Pubitemid 36245802)